The MTC-Y™ Carrier System study
In vivo PK study results – A comparison of Subcutaneous Injection to Transdermal Insulin Administration
Study design
The study was conducted using:
Subcutaneous injection (semaglutide – 0.3 mg/kg)
Biotts MTC-S1 ointment (semaglutide – 2.0 mg)
The study utilized rats as subjects and consisted of two groups. The first group received a single injection, while the second group had the ointment applied once, followed by occlusion for 3 days.
Results
Absolute bioavailability for MTC-S1 ointment was 4% – which is 5 to 10 times higher than current oral market solution.
Development collaborations
The MTC-Y™ carrier technology is the foundation of Biotts’ transdermal drug product development pipeline, but it’s also available to the pharmaceutical industry through contract development collaborations. Contact us or further information.